AI Science Tracker

Taipei Medical University

1 discovery from 2024

Discoveries

Ensemble machine learning identified CDK8 inhibitor hits

A six-model ensemble classified 1.6 million commercial molecules and reduced them to a 1,672-compound CDK8-focused screening library. Docking and visual inspection selected 25 candidates for enzymatic assays; six showed CDK8 inhibition. The most potent hit, T479-0984, had a reported IC50 of 99.9 nM. The paper reports low structural similarity (Tanimoto <0.300) to a comparison set of 30 diverse known CDK8 inhibitors. These are assay hits and starting points, not validated drugs or evidence of therapeutic efficacy.

Technology: Six-model ensemble classifier (logistic regression, k-nearest neighbors, support vector classification, random forest, XGBoost and multilayer perceptron)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Twenty-five candidates from the focused library underwent CDK8 enzymatic testing; six showed inhibition. T479-0984 was reported with IC50 99.9 nM. The paper compared hits against 30 diverse known CDK8 inhibitors and reports Tanimoto similarity below 0.300.
  • Still unknown: The assay establishes in-vitro enzyme inhibition only, not cellular target engagement, animal efficacy, clinical utility, or exhaustive prior patent/publication status for the compounds.
  • AI role: The six-model ensemble filtered a 1.6-million-molecule commercial library into a 1,672-molecule CDK8-focused library; docking and visual inspection selected candidates that were then tested enzymatically.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11081523/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary PMC full text, article metadata, methods/results, author affiliations and compound-level structural comparison reviewed..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.